TY - JOUR
T1 - Effect of prostaglandin D2 on VEGF release by nasal polyp fibroblasts
AU - Kanai, Kengo
AU - Okano, Mitsuhiro
AU - Fujiwara, Tazuko
AU - Kariya, Shin
AU - Haruna, Takenori
AU - Omichi, Ryotaro
AU - Makihara, Sei ichiro
AU - Hirata, Yuji
AU - Nishizaki, Kazunori
N1 - Funding Information:
The authors would like to thank Yuko Okano for her editorial assistance. This work was supported in part by grants from Ministry of Education,Culture,Sports,Science,and Technology of Japan ( 15H01987 and 26670742 ).
Publisher Copyright:
© 2016 Japanese Society of Allergology
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Background Vascular endothelial growth factor (VEGF) is known to be associated with the pathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNP). VEGF is produced by a variety of cells including fibroblasts. It was recently reported that prostaglandin (PG) E2 induces VEGF release by nasal polyp fibroblasts. However, little is known regarding possible regulation of VEGF by other PGs. We have reported that molecules that regulate PGD2 metabolism play roles in the pathogenesis of CRS including in local eosinophilia and type 2 cytokine production. In the present study, we sought to determine whether PGD2 regulates VEGF release by nasal polyp fibroblasts. Methods Nasal polyp fibroblasts were established from nasal polyps. These fibroblasts were stimulated with serial dilutions of PGD2 or PGD2 receptor (DP/CRTH2)-selective agonists in the presence or absence of receptor-selective antagonists. The concentration of VEGF in the culture supernatants was determined using ELISA. Results 5 μM of PGD2 significantly induced VEGF release by nasal polyp fibroblasts. VEGF release was also obtained by stimulation with a DP receptor-selective, but not with a CRTH2 receptor-selective agonist. In addition, PGD2-induced VEGF release was significantly inhibited by pre-treatment with DP receptor-selective antagonists. In contrast, pre-treatment with a CRTH2 receptor-selective antagonist significantly enhanced PGD2-induced VEGF release. Conclusions PGD2 stimulates VEGF production via DP but not CRTH2 receptors in nasal polyp fibroblasts.
AB - Background Vascular endothelial growth factor (VEGF) is known to be associated with the pathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNP). VEGF is produced by a variety of cells including fibroblasts. It was recently reported that prostaglandin (PG) E2 induces VEGF release by nasal polyp fibroblasts. However, little is known regarding possible regulation of VEGF by other PGs. We have reported that molecules that regulate PGD2 metabolism play roles in the pathogenesis of CRS including in local eosinophilia and type 2 cytokine production. In the present study, we sought to determine whether PGD2 regulates VEGF release by nasal polyp fibroblasts. Methods Nasal polyp fibroblasts were established from nasal polyps. These fibroblasts were stimulated with serial dilutions of PGD2 or PGD2 receptor (DP/CRTH2)-selective agonists in the presence or absence of receptor-selective antagonists. The concentration of VEGF in the culture supernatants was determined using ELISA. Results 5 μM of PGD2 significantly induced VEGF release by nasal polyp fibroblasts. VEGF release was also obtained by stimulation with a DP receptor-selective, but not with a CRTH2 receptor-selective agonist. In addition, PGD2-induced VEGF release was significantly inhibited by pre-treatment with DP receptor-selective antagonists. In contrast, pre-treatment with a CRTH2 receptor-selective antagonist significantly enhanced PGD2-induced VEGF release. Conclusions PGD2 stimulates VEGF production via DP but not CRTH2 receptors in nasal polyp fibroblasts.
KW - CRTH2
KW - DP
KW - Nasal polyp fibroblast
KW - PGD2
KW - VEGF
UR - http://www.scopus.com/inward/record.url?scp=84963641643&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84963641643&partnerID=8YFLogxK
U2 - 10.1016/j.alit.2016.03.003
DO - 10.1016/j.alit.2016.03.003
M3 - Article
C2 - 27091669
AN - SCOPUS:84963641643
SN - 1323-8930
VL - 65
SP - 414
EP - 419
JO - Allergology International
JF - Allergology International
IS - 4
ER -